Physiological Basis
Platelet-rich fibrin (PRF) is a second-generation autologous platelet concentrate derived from the patient's own venous blood. Unlike first-generation platelet-rich plasma (PRP), PRF is produced without anticoagulants, activating agents, or exogenous thrombin — the blood is centrifuged at low speed (approximately 1,500 RPM for 12–14 minutes), allowing the blood's intrinsic coagulation cascade to produce a natural fibrin clot. This fibrin scaffold acts as a three-dimensional matrix that entraps platelets, white blood cells, and a concentrated reservoir of growth factors: vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), insulin-like growth factor 1 (IGF-1), and epidermal growth factor (EGF).
The fibrin matrix is the key distinction between PRF and PRP. Rather than releasing growth factors in a single rapid bolus upon platelet activation, the PRF scaffold allows slow, sustained release of bioactive molecules over several days at the injection site — a pharmacokinetic advantage that is thought to prolong the angiogenic and tissue-regenerative stimulus within the corpus cavernosum. When injected into the corpora cavernosa or sub-glans space, these growth factors collectively drive neovascularisation, activate Schwann cells to support peripheral nerve regeneration, and promote restoration of elastin content and smooth muscle cell integrity in the tunica albuginea and cavernosal tissue.
Because PRF is derived entirely from the patient's own blood, immune-mediated rejection, hypersensitivity reactions, and disease transmission risks are eliminated. The autologous nature also removes regulatory complexity — PRF processing does not constitute pharmaceutical manufacturing and falls within physician-directed autologous blood procedures.
The Treatment Protocol
A venous blood draw of 20 to 60 mL is performed using standard phlebotomy technique. The blood is immediately transferred to sterile centrifuge tubes without anticoagulant and centrifuged at 1,500 RPM for 12 to 14 minutes using a low-speed centrifugation protocol. This produces three distinct layers: a red blood cell base, a buffy coat of white blood cells, and an upper liquid PRF layer — which is aspirated and prepared for injection. Unlike PRP, no activation step (thrombin, calcium chloride) is required; the fibrin polymerisation has already begun during centrifugation and the product is injectable as a viscous liquid immediately.
Topical anaesthetic cream (EMLA) is applied to the injection sites 30 to 45 minutes prior to the procedure, with optional supplementation by a penile dorsal nerve block with lidocaine for patients preferring maximal comfort. Using a small-gauge needle (27–30 gauge), intra-cavernosal injections are delivered bilaterally at multiple sites along the penile shaft, with additional sub-glans injection as indicated by the clinical objective. Multiple injection points ensure even distribution of the fibrin matrix throughout the target tissue. The procedure is performed under sterile technique. Patients are observed for 15 to 30 minutes post-procedure to confirm haemostasis and absence of adverse response before discharge.
Who is a Candidate
PRF injection therapy is best indicated for patients with mild-to-moderate organic erectile dysfunction with partially preserved vascular function — the angiogenic stimulus of PRF growth factors augments existing capacity rather than replacing it entirely. Additional indications include early-phase Peyronie's disease (acute inflammatory phase, prior to plaque consolidation), where growth factor delivery may modulate the fibrotic process; post-surgical sensitivity reduction following radical prostatectomy or penile reconstruction; and as an adjunct to shockwave therapy or optimised PDE5 inhibitor protocols. The combination of Li-ESWT with PRF injection is an increasingly utilised protocol at SMSNA-affiliated centres, with shockwave treatment administered first to prime the angiogenic environment and PRF injections following within 48 to 72 hours.
PRF injection is not appropriate for patients with active platelet dysfunction, thrombocytopenia (platelet count below 100,000/μL), or those receiving anticoagulation therapy with warfarin or novel oral anticoagulants. Active penile infection or inflammation, haematological malignancy, and allergy to local anaesthetic agents are contraindications. Patients should have completed fertility planning, as the minor physical trauma of injection carries theoretical considerations in the context of ongoing fertility treatment cycles.
Expected Outcomes and Timeline
The clinical evidence base for PRF in erectile dysfunction is in an active development phase, with published data demonstrating improvement in IIEF (International Index of Erectile Function) domain scores and penile sensitivity measures that are comparable to, and in some series superior to, conventional PRP results. The theoretical advantage of the fibrin scaffold's sustained-release kinetics — prolonged growth factor delivery versus PRP's rapid bolus release — is supported by in-vitro and early clinical data, though head-to-head comparative trials remain limited. Most treating clinicians recommend a series of 2 to 4 treatments spaced 4 to 6 weeks apart to achieve cumulative tissue-level effect. Patients are counselled that biological tissue remodelling is a gradual process; meaningful improvement in erectile response is typically first noted at 4 to 8 weeks following initial treatment, with full assessment of response deferred until 1 to 3 months post-course completion.
PRF injection is best framed as one component within a multimodal regenerative protocol rather than a standalone curative treatment for moderate-to-severe erectile dysfunction. Patients with mild ED, post-prostatectomy nerve injury in the recovery phase, or sensitivity concerns tend to report the most clinically significant subjective benefit. Re-treatment at 12-month intervals is a common maintenance strategy in responding patients.
Safety Profile and Risks
The safety profile of autologous PRF injection is excellent. Because the injectate is derived entirely from the patient's own blood, immune-mediated complications, allergic reactions, and disease transmission are not applicable risks. The most common adverse effects are local and transient: bruising at the blood draw site, mild discomfort and transient swelling at the intra-cavernosal injection sites, and occasional minor ecchymosis. Serious complications are rare. Infection risk, while theoretical, is minimised by strict sterile technique. Haematoma formation within the corpus cavernosum is uncommon with appropriately sized needles and adequate post-procedure compression.
Cost and Accessibility
PRF injection is priced per session, with most centres offering series pricing for the recommended 2 to 4 treatment course. The variable cost is primarily the physician's time — the consumable cost of centrifuge tubes, sterile supplies, and local anaesthetic is modest. Clinical-grade centrifuges suitable for PRF processing represent a capital investment, but this is shared across all patients treated. PRF injection is a cash-pay procedure with no current insurance coverage for erectile dysfunction indications.
Selecting a Qualified Provider
Physicians performing PRF regenerative injection for erectile dysfunction should hold ABU board certification in urology and ideally maintain active SMSNA membership, reflecting engagement with the evolving evidence base in sexual medicine. Specific training in intra-cavernosal injection technique is essential — the sub-dartos and intra-cavernosal planes require precise anatomical knowledge to avoid inadvertent injection into incorrect tissue layers, vascular structures, or the urethra. Providers should be able to describe their specific centrifugation protocol, the growth factor concentration methodology they use, and their clinical criteria for patient selection. Centres that combine PRF with Li-ESWT in a structured protocol, rather than offering isolated injections without diagnostic workup, reflect the higher standard of care in this emerging subspecialty.